EDNRA Overview
Molecule Name
Endothelin receptor type A
Synonyms
endothelin receptor type A, ETA,ET-A,ETAR,ETRA,MFDA,ETA-R,hET-AR
Drug Development Progress
Drugs in Clinical Trials11
Approved Drugs8
Highest Development StageApproved
Target Synonym
Endothelin Receptor Type A，EDNRA，ETA-R，Endothelin-1 receptor，hET-AR，ETRA，ET-A，ETA，Endothelin-1-Specific Receptor，Endothelin Receptor Subtype A，G Protein-Coupled Receptor，ETAR，MFDA，Receptor， Endothelin A
Background
EDNRA encodes the endothelin type A receptor, a G protein-coupled receptor mediating vasoconstriction and cell proliferation upon endothelin-1 binding. Overexpression contributes to pulmonary arterial hypertension, cardiovascular disorders, and cancer progression. Selective EDNRA antagonists offer therapeutic potential for managing hypertension, fibrosis, and tumor angiogenesis.
EDNRA Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SC-0062 | SC-0062; WX-013 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Altitude Sickness; Diabetic Nephropathies; Glomerulonephritis, IGA; Kidney Diseases; Pulmonary Arterial Hypertension | Details |
| Zibotentan/Dapagliflozin | Phase 3 Clinical | Astrazeneca Ab, AstraZeneca global R & D (China) Co Ltd | Albuminuria; Kidney Diseases; Renal Insufficiency, Chronic | Details | |
| Patecibart | GMA-301; GMA-301-A; GMA-301-B | Phase 2 Clinical | Gmax Biopharm Llc | Pulmonary Arterial Hypertension | Details |
| Zibotentan | ZD-4054; AZD-4054 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hepatic Insufficiency; Hypertension, Portal; Intermittent Claudication; Liver Cirrhosis; Lung Neoplasms; Metastatic breast cancer; Microvascular Angina; Neoplasm Metastasis; Ovarian Neoplasms; Peripheral Arterial Disease; Prostatic Neoplasms; Renal Insufficiency; Renal Insufficiency, Chronic; Scleroderma, Limited; Scleroderma, Systemic; Solid tumours | Details |
| SAL-0120 | SAL-0120; SAL0120 | Phase 2 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Essential Hypertension; Glomerulonephritis, IGA; Hypertension; Renal Insufficiency, Chronic | Details |
| HS-10390 | HS-10390; HS10390 | Phase 2 Clinical | Changzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Glomerulonephritis, IGA; Glomerulosclerosis, Focal Segmental; Renal Insufficiency, Chronic | Details |
| BQ-123 | CGS-26343; BQ-123; PMZ-2123 | Phase 1 Clinical | Midwestern University | Cardiovascular Diseases; Coronary Artery Disease; Diabetic Ketoacidosis; Heart Failure; Hypertension; Hypertension, Pulmonary; Hypoxia, Brain; Metabolic Syndrome; Multiple System Atrophy; Pain; Proteinuria; Pure Autonomic Failure; Renal Insufficiency, Chronic; ST Elevation Myocardial Infarction | Details |
| GMA-131 | GMA-131 | Phase 1 Clinical | Gmax Biopharm Llc, Gmaxx Biologics Ltd | Diabetic Nephropathies | Details |
| AK-1960 | AK1960; AK-1960 | Phase 1 Clinical | Renal Insufficiency, Chronic | Details | |
| GLX-002 | GLX-002; GLX002 | Phase 1 Clinical | Yabao Pharmaceutical Co Ltd Beijing | Pulmonary Arterial Hypertension | Details |
| Bosentan Orally Disintegrating Tablets(Beijing Sunho Pharma) | Phase 1 Clinical | Beijing Sunho Pharmaceutical Co Ltd | Pulmonary Arterial Hypertension | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Clazosentan Sodium | Ro-61-1790; ACT-108475; AXV-034; VML-588; AXV-034343 | Approved | F. Hoffmann-La Roche Ltd | Pivlaz | Japan | Subarachnoid Hemorrhage; Brain Ischemia; Vasospasm, Intracranial; Cerebral Infarction | Idorsia Pharmaceuticals Ltd | 2022-01-20 | Aneurysm; Brain Ischemia; Cerebral Infarction; Subarachnoid Hemorrhage; Vasospasm, Intracranial | Details |
| Macitentan/Tadalafil | Approved | Actelion Pharmaceuticals Ltd | OPSYNVI, Yuvanci | United States | Pulmonary Arterial Hypertension | Actelion Pharmaceuticals Us Inc | 2024-03-22 | Phenylketonurias; Pulmonary Arterial Hypertension | Details | |
| Ambrisentan | LU-208075; BSF-208075; GSK-132576A | Approved | Abbott Laboratories | Letairis, Volibris, 凡瑞克 | United States | Pulmonary Arterial Hypertension | Gilead Sciences Inc | 2007-06-15 | Acute Kidney Injury; Anemia, Sickle Cell; Ascites; Coronavirus Disease 2019 (COVID-19); Hepatorenal Syndrome; Hypertension; Hypertension, Portal; Hypertension, Pulmonary; Hypoxia; Idiopathic Pulmonary Fibrosis; Liver Cirrhosis; Pulmonary Arterial Hypertension; Sarcoidosis; Scleroderma, Systemic; Thromboembolism; Vascular Diseases | Details |
| Sparsentan | PS-433540; BMS-346567; RE-021 | Approved | Bristol-Myers Squibb Company | Filspari | United States | Glomerulonephritis, IGA | Travere Therapeutics Inc | 2023-02-17 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases; Cardiovascular Diseases; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulosclerosis, Focal Segmental; Hypertension; Immune System Diseases; Kidney Diseases; Nephritis, Hereditary; Nephrosis, Lipoid; Proteinuria; Purpura, Schoenlein-Henoch | Details |
| Bosentan Hydrate | ACT-050088; HGP-1206; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039 | Approved | F. Hoffmann-La Roche Ltd | Stayveer, 全可利, Tracleer | United States | Pulmonary Arterial Hypertension | Actelion Pharmaceuticals Ltd | 2001-11-20 | Anemia, Sickle Cell; Chronic thromboembolic pulmonary hypertension; Coronary Vasospasm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fibrosis; Giant Cell Arteritis; Glaucoma; Heart Defects, Congenital; Heart Septal Defects, Atrial; Hepatopulmonary Syndrome; Hypertension; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Liver Cirrhosis; Lung Diseases, Interstitial; Persistent Fetal Circulation Syndrome; Pulmonary Arterial Hypertension; Pulmonary Fibrosis; Sarcoidosis; Scleroderma, Systemic; Sleep Apnea Syndromes; Takayasu Arteritis; Ulcer; Vasculitis | Details |
| Macitentan | ACT-064992; Actelion-1; JNJ-67896062 | Approved | Actelion Pharmaceuticals Ltd | Zependo, Opsumit, 傲朴舒 | United States | Pulmonary Arterial Hypertension | Actelion Pharmaceuticals Us Inc | 2013-10-18 | Anemia, Sickle Cell; Angina Pectoris; Chronic Disease; Chronic thromboembolic pulmonary hypertension; Eisenmenger Complex; Glioblastoma; Heart Defects, Congenital; Heart Failure; Heart Failure, Diastolic; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Pulmonary Arterial Hypertension; Pulmonary Embolism; Scleroderma, Systemic; Scleroderma-associated interstitial lung diseases; Thromboembolism; Ulcer | Details |
| Aprocitentan | ACT-132577; AC-080; JNJ-2820 | Approved | Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd | TRYVIO, JERAYGO | United States | Hypertension | Idorsia Pharmaceuticals Ltd | 2024-03-19 | Essential Hypertension; Hepatic Insufficiency; Hypertension; Renal Insufficiency, Chronic | Details |
| Atrasentan hydrochloride | ABT-147627; (+)-A-127722; Abbott-147627; A-147627; ABT-627; A-1476271; CHK-01; EXV 811 | Approved | Abbvie Inc | Vanrafia, 诺锐达, Xinlay | United States | Glomerulonephritis, IGA; Proteinuria | Novartis Pharmaceutical Corp, Novartis Pharma Ag | 2025-04-02 | Abdominal Neoplasms; Adenocarcinoma; CNS Embryonal Tumor; Diabetes Mellitus; Diabetic Nephropathies; Fallopian Tube Neoplasms; Glomerulonephritis, IGA; Glomerulosclerosis, Focal Segmental; Kidney Diseases; Kidney Neoplasms; Neoplasm Metastasis; Nephritis, Hereditary; Ovarian Neoplasms; Prostatic Neoplasms; Proteinuria; Renal Insufficiency, Chronic; Vascular Diseases | Details |